Fig. 5From: RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trialAssessments during treatment and administration of treatment (cycle 1). PK pharmacokineticsBack to article page